In-utero exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review

Catherine A Fitton, Markus F C Steiner, Lorna Aucott, Jill P Pell, Daniel F Mackay, Michael Fleming, James S McLay, Catherine A Fitton, Markus F C Steiner, Lorna Aucott, Jill P Pell, Daniel F Mackay, Michael Fleming, James S McLay

Abstract

Background: Although medication is generally avoided wherever possible during pregnancy, pharmacotherapy is required for the treatment of pregnancy associated hypertension, which remains a leading cause of maternal and fetal morbidity and mortality. The long-term effects to the child of in-utero exposure to antihypertensive agents remains largely unknown.

Objective: The aim of this study was to systematically review published studies on adverse outcomes to the child associated with in-utero exposure to antihypertensive medications.

Methods: OVID, Scopus, EBSCO Collections, the Cochrane Library, and Web of Science databases were searched for relevant publications published between January 1950 and October 2016 and a total of 688 potentially eligible studies were identified.

Results: Following review, 47 primary studies were eligible for inclusion. The Critical Appraisal Skills Programme checklist was used to assess study quality. Five studies were of excellent quality; the remainder were either mediocre or poor. Increased risk of low birth weight, low size for gestational age, preterm birth, and congenital defects following in-utero exposure to all antihypertensive agents were identified. Two studies reported an increased risk of attention deficit hyperactivity disorder following exposure to labetalol, and an increased risk of sleep disorders following exposure to methyldopa and clonidine.

Conclusion: The current systematic review demonstrates a paucity of relevant published high-quality studies. A small number of studies suggest possible increased risk of adverse child health outcomes; however, most published studies have methodological weaknesses and/or lacked statistical power thus preventing any firm conclusions being drawn.

References

    1. Wilkinson H. Trustees and Medical Advisers. Saving mothers’ lives. Reviewing maternal deaths to make motherhood safer: 2006–2008. BJOG 2011; 118:1402–1403.
    1. Lindheimer MD, Taler SJ, Cunningham FG. Hypertension in pregnancy. J Am Soc Hypertens 2010; 4:68–78.
    1. Lo JO, Mission JF, Caughey AB. Hypertensive disease of pregnancy and maternal mortality. Curr Opin Obstet Gynecol 2013; 25:124–132.
    1. James PR, Nelson-Piercy C. Management of hypertension before, during, and after pregnancy. Heart 2004; 90:1499.
    1. Scantlebury DC, Schwartz GL, Acquah LA, White WM, Moser M, Garovic VD. The treatment of hypertension during pregnancy: when should blood pressure medications be started? Curr Cardiol Rep 2013; 15:412.
    1. Koren G. Systematic review of the effects of maternal hypertension in pregnancy and antihypertensive therapies on child neurocognitive development. Reprod Toxicol 2013; 39:1–5.
    1. Loebstein R, Koren G. Clinical relevance of therapeutic drug monitoring during pregnancy. Ther Drug Monit 2002; 24:15–22.
    1. Wagner CL, Katikaneni LD, Cox TH, Ryan RM. The impact of prenatal drug exposure on the neonate. Obstet Gynecol Clin North Am 1998; 25:169–194.
    1. Bulloch MN, Carroll DG. When one drug affects 2 patients: a review of medication for the management of nonlabor-related pain, sedation, infection, and hypertension in the hospitalized pregnant patient. J Pharm Pract 2012; 25:352–367.
    1. Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2013; CD001449.
    1. Chan WS, Koren G, Barrera M, Rezvani M, Knittel-Keren D, Nulman I. Neurocognitive development of children following in-utero exposure to labetalol for maternal hypertension: a cohort study using a prospectively collected database. Hypertens Pregnancy 2010; 29:271–283.
    1. Davis RL, Eastman D, Mcphillips H, Raebel MA, Andrade SE, Smith D, et al. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf 2011; 20:138–145.
    1. Pasker-De Jong PC, Zielhuis GA, Van Gelder MM, Pellegrino A, Gabreels FJ, Eskes TK. Antihypertensive treatment during pregnancy and functional development at primary school age in a historical cohort study. BJOG 2010; 117:1080–1086.
    1. Brown MA, Buddle ML, Farrell T, Davis GK. Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. Obstet Gynecol 2002; 187:1046–1050.
    1. Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension 2008; 51:960–969.
    1. Khan K, Zamora J, Lamont RF, Van GH, Svare J, Santos-Jorge C, et al. Safety concerns for the use of calcium channel blockers in pregnancy for the treatment of spontaneous preterm labour and hypertension: a systematic review and meta-regression analysis. J Matern Fetal Neonatal Med 2010; 23:1030–1038.
    1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. PLoS Med 2009; 6:E1000100.
    1. Critical Appraisal Skills Programme (2017). CASP (Checklist for Randomised Controlled Trials) Checklist. [online] Available at: .
    1. Critical Appraisal Skills Programme (2017). CASP (Case Control Studies) Checklist. [online] Available at: .
    1. Critical Appraisal Skills Programme (2017). CASP (Checklist for Cohort Studies) Checklist. [online] Available at: .
    1. Fitton C, Steiner M, Aucott L, Pell J, Fleming M, McLay J, In utero exposure to antihypertensive medication during pregnancy and neonatal and child health outcome. PROSPERO International prospective register of systematic reviews [Internet]; 2016. Available from: .
    1. Diav-Citrin O, Shechtman S, Halberstadt Y, Finkel-Pekarsky V, Wajnberg R, Arnon J, et al. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reprod Toxicol 2011; 31:540–545.
    1. Magee LA, Schick B, Donnenfeld AE, Sage SR, Conover B, Cook L, et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Obstet Gynecol 1996; 174:823–828.
    1. Weber-Schoendorfer C, Hannemann D, Meister R, Eléfant E, Cuppers-Maarschalkerweerd B, Arnon J, et al. The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study. Reprod Toxicol 2008; 26:24–30.
    1. Olesen C, De Vries C, Thrane S, Macdonald N, Larsen TM, SÃ H, et al. Effect of diuretics on fetal growth: a drug effect or confounding by indication? Pooled Danish and Scottish cohort data. Br J Clin Pharmacol 2000; 51:153–157.
    1. Banhidy F, Acs N, Puho EH, Czeizel AE. The efficacy of antihypertensive treatment in pregnant women with chronic and gestational hypertension: a population-based study. Hypertens Res 2010; 33:460–466.
    1. Caton AR, Bell EM, Druschel CM, Werler MM, Mitchell AA, Browne ML, et al. Maternal hypertension, antihypertensive medication use, and the risk of severe hypospadias. Birth Defects Res A Clin Mol Teratol 2008; 82:34–40.
    1. Caton AR, Bell EM, Druschel CM, Werler MM, Lin AE, Browne ML, et al. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension 2009; 54:63–70.
    1. Lennestål R, Otterblad Olausson P, Källén B. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol 2009; 65:615–625.
    1. Van Gelder MM, Van Bennekom CM, Louik C, Werler MM, Roeleveld N, Mitchell AA. Maternal hypertensive disorders, antihypertensive medication use, and the risk of birth defects: a case-control study. BJOG 2015; 122:1002–1009.
    1. Nakhai-Pour HR, Rey E, Bérard A. Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns. Birth Defects Res B Dev Reprod Toxicol 2010; 89:147–154.
    1. Arias F, Zamora J. Antihypertensive treatment and pregnancy outcome in patients with mild chronic hypertension. Obstet Gynecol 1979; 53:489–494.
    1. Bateman BT, Huybrechts KF, Maeda A, Desai R, Patorno EDH, Seely EW, et al. Calcium channel blocker exposure in late pregnancy and the risk of neonatal seizures. Obstet Gynecol 2015; 126:271–278.
    1. Parazzini F, Benedetto C, Bortolus R, Ricci E, Marozio L, Donvito V, et al. Nifedipine versus expectant management in mild to moderate hypertension in pregnancy. BJOG 1998; 105:718–722.
    1. Sorensen HT, Czeizel AE, Rockenbauer M, Steffensen FH, Olsen J. The risk of limb deficiencies and other congenital abnormalities in children exposed in utero to calcium channel blockers. Acta Obstet Gynecol Scand 2001; 80:397–401.
    1. Bortolus R, Ricci E, Chatenoud L, Parazzini F. Nifedipine administered in pregnancy: effect on the development of children at 18 months. BJOG 2000; 107:792–794.
    1. Bayliss H, Churchill D, Beevers M, Beevers DG. Anti-hypertensive drugs in pregnancy and fetal growth: evidence for ‘pharmacological programming’ in the first trimester? Hypertens Pregnancy 2002; 21:161–174.
    1. Heida KY, Zeeman GG, Van Veen TR, Hulzebos CV. Neonatal side effects of maternal labetalol treatment in severe preeclampsia. Early Hum Dev 2012; 88:503–507.
    1. Lip GYH, Beevers M, Churchill D, Shaffer LM, Beevers DG. Effect of atenolol on birth weight. Am J Cardiol 1997; 79:1436–1438.
    1. Meidahl Petersen K, Jimenez-Solem E, Andersen JT, Petersen M, Brødbæk K, Køber L, et al. β-blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open 2012; 2:e001185.
    1. Munshi UK, Deorari AK, Paul VK, Singh M. Effects of maternal labetalol on the newborn infant. Indian Pediatr 1992; 29:1507.
    1. Pickles CJ, Broughton Pipkin F, Symonds EM. A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. Br J Obstet Gynaec 1992; 99:964–968.
    1. Ray JG, Vermeulen MJ, Burrows EA, Burrows RF. Use of antihypertensive medications in pregnancy and the risk of adverse perinatal outcomes: Mcmaster Outcome Study of Hypertension in Pregnancy 2 (MOS HIP 2). BMC Pregnancy Childbirth 2001; 1:1–8.
    1. Rubin P, Clark D, Sumner D, Low R, Butters L, Reynolds B, et al. Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet 2016; 321:432–434.
    1. Lydakis C, Lip GYH, Beevers M, Beevers DG. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 1999; 12:541–547.
    1. Lieberman BA, Stirrat GM, Cohen SL, Beard RW, Pinker GD, Belsey E. The possible adverse effect of propranolol on the fetus in pregnancies complicated by severe hypertension. BJOG 1978; 85:678–683.
    1. Sibai BM, Gonzalez AR, Mabie WC, Moretti M. A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. Obstet Gynecol 1987; 70 (3 Pt 1):323–327.
    1. Macpherson M, Pipkin FB, Rutter N. The effect of maternal labetalol on the newborn infant. BJOG 1986; 93:539–542.
    1. Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1982; 1:647–649.
    1. Weitz C, Khouzami V, Maxwell K, Johnson JWC. Treatment of hypertension in pregnancy with methyldopa: a randomized double blind study. Int J Gynaecol Obstet 1987; 25:35–40.
    1. Orbach H, Matok I, Gorodischer R, Sheiner E, Daniel S, Wiznitzer A, et al. Hypertension and antihypertensive drugs in pregnancy and perinatal outcomes. Obstet Gynecol 2013; 208:301.e1–301.e6.
    1. Fidler J, Smith V, Fayers P, De Swiet M. Randomised controlled comparative study of methyldopa and oxprenolol in treatment of hypertension in pregnancy. Br Med J (Clin Res Ed) 1983; 283:1927.
    1. Plouin P, Breart G, Maillard F, Papiernik E, Relier J. Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial. Br J Obstet Gynaec 1988; 95:868–876.
    1. Sibai BM, Mabie WC, Shamsa F, Villar MA, Anderson GD. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Obstet Gynecol 1990; 162:960–967.
    1. Gazzolo D, Visser GHA, Russo A, Scopesi F, Santi F, Bruschettini PL. Pregnancy-induced hypertension, antihypertensive drugs and the development of fetal behavioural states. Early Hum Dev 1998; 50:149–157.
    1. Karthikeyan VJ, Ferner RE, Baghdadi S, Lane DA, Lip GYH, Beevers DG. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnancies. J Hypertens 2011; 29:396–399.
    1. Li D, Yang C, Andrade S, Tavares V, Ferber JR. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 2011; 343:d5931.
    1. Moretti ME, Caprara D, Drehuta I, Yeung E, Cheung S, Federico L, et al. The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Obstet Gynecol Int 2011; 2012:658310.
    1. Tabacova S, Little R, Tsong Y, Vega A, Kimmel CA. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol Drug Saf 2003; 12:633–646.
    1. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354:2443–2451.
    1. Huisjes HJ, Hadders-Algra M, Touwen BC. Is clonidine a behavioural teratogen in the human? Early Hum Dev 1986; 14:43–48.
    1. Hall DR, Odendaal HJ, Steyn DW, Smith M. Nifedipine or prazosin as a second agent to control early severe hypertension in pregnancy: a randomised controlled trial. BJOG 2000; 107:759–765.
    1. Fenakel K, Fenakel G, Appelman Z, Lurie S, Katz Z, Shoham Z. Nifedipine in the treatment of severe preeclampsia. Obstet Gynecol 1991; 77:331–337.
    1. Vigil-De Gracia P, Lasso M, Ruiz E, Vega-Malek JC, De Mena FT, López JC. Severe hypertension in pregnancy: hydralazine or labetalol: a randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2006; 128:157–162.
    1. Xie R, Guo Y, Krewski D, Mattison D, Walker MC, Nerenberg K, et al. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. Eur J Obstet Gynecol Reprod Biol 2014; 175:124–128.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe